2-amino-5-(diaminomethylideneamino)-N-[1-[[5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-5-(diaminomethylideneamino)-N-[1-[[5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide
• 化学式: C₄₃H₆₉N₁₁O₃
• 分子量: 788.1
• InChiKey: ZVOYWSKEBVVLGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  57
• 可旋转键数：
  21
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  258
• 氢给体数：
  9
• 氢受体数：
  6

文献信息

• TREATMENT OF BIOFILMS
  申请人：Stensen Wenche

  公开号：US20110236453A1

  公开（公告）日：2011-09-29

  The present invention relates to a peptide or peptidomimetic for use in the treatment of a biofilm-associated infection in a subject, wherein said peptide or peptidomimetic a) carries a net positive charge, b) is 1 to 6 amino acids in length or is an equivalently sized peptidomimetic; and c) is amphipathic in nature, having one or more lipophilic groups, one of said lipophilic groups comprising at least 7 non-hydrogen atoms.

  本发明涉及用于治疗生物膜相关感染的肽或类肽，其中所述肽或类肽a）具有净正电荷，b）长度为1至6个氨基酸或等效大小的类肽；c）是两性的，具有一个或多个亲脂性基团，其中一个亲脂性基团含有至少7个非氢原子。
• FLOUROUS METABOLICALLY STABLE PEPTIDE ANALOGS
  申请人：Université de Strasbourg

  公开号：EP3257863A1

  公开（公告）日：2017-12-20

  The present invention relates to metabolically stable and non-immunogen analogs completely hydrosoluble at physiological pH, and their use for the prevention or treatment of diseases mediated by G-protein coupled receptor (GPCR), in particular (Central Nervous System) CNS and cardiovascular diseases or disorders.

  本发明涉及在生理 pH 值下完全水溶的代谢稳定的非免疫原类似物，以及它们在预防或治疗由 G 蛋白偶联受体（GPCR）介导的疾病，特别是（中枢神经系统）中枢神经系统和心血管疾病或紊乱方面的用途。
• ANTIMICROBIAL COMPOUNDS
  申请人：Stensen Wenche

  公开号：US20110172145A1

  公开（公告）日：2011-07-14

  The present invention relates to a compound of formula (I) AA-AA-AA-X—Y—Z wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; X is a N atom, which may be substituted by a branched or unbranched C 1 -C 10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from —R a —R b —, —R a —R b —R b — and —R b —R b —R a — wherein R a is C, O, S or N, and R b is C; each of R a and R b may be substituted by C 1 -C 4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between R a or R b of Y and a non-hydrogen atom of one of the cyclic groups of Z. The invention further relates to formulations containing these compounds and their uses in therapy, particularly as antimicrobial or antitumoural agents.
• US9085608B2
  申请人：——

  公开号：US9085608B2

  公开（公告）日：2015-07-21